BTK and diffuse large B-cell lymphoma: In this study, to determine whether BTK inhibitor-based drug combination therapy can benefit the treatment of diffuse large B-cell lymphoma, we play proliferation assay with an appropriate concentration of Apigenin in combination with low-dose Abivertinib in U2932 and OCI-LY10 for 48 hours.